Morgan Stanley Raises Insmed (NASDAQ:INSM) Price Target to $144.00

Key Points

• Morgan Stanley has raised Insmed's price target from $126.00 to $144.00, indicating a potential upside of 11.24% from the stock's previous close.
• Insmed's stock has received multiple upgrades from other analysts, with overall positive sentiment reflected in a "Moderate Buy" average rating and a target price of $132.57.
• Despite missing earnings estimates with a reported EPS of ($1.70), Insmed's revenue for the quarter grew by 18.9% year-over-year, reaching $107.42 million.

Insmed (NASDAQ:INSM - Get Free Report) had its target price raised by research analysts at Morgan Stanley from $126.00 to $144.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target suggests a potential upside of 11.24% from the stock's previous close.

INSM has been the topic of several other research reports. Royal Bank Of Canada increased their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. The Goldman Sachs Group increased their price target on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Truist Financial increased their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. UBS Group increased their price target on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Finally, Citigroup raised shares of Insmed to a "buy" rating in a research report on Tuesday, June 10th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $132.57.

Insmed Stock Performance

Shares of INSM stock opened at $129.45 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed has a one year low of $60.40 and a one year high of $130.13. The company's 50-day simple moving average is $106.10 and its 200-day simple moving average is $84.93. The stock has a market capitalization of $27.36 billion, a price-to-earnings ratio of -22.67 and a beta of 0.95.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the business posted ($1.94) EPS. The business's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 504,694 shares of company stock valued at $48,660,104 over the last quarter. Insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Insmed

Several large investors have recently made changes to their positions in INSM. M&T Bank Corp grew its position in Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after buying an additional 147 shares during the last quarter. Snowden Capital Advisors LLC grew its position in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares during the last quarter. First Horizon Advisors Inc. grew its position in Insmed by 24.8% in the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 186 shares during the last quarter. ORG Partners LLC grew its position in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 196 shares during the last quarter. Finally, Cullen Frost Bankers Inc. grew its position in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.